Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Autor:	Daley CL; Department of Medicine, National Jewish Health, Denver, Colorado, USA.; Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Iaccarino JM; Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA., Lange C; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.; German Center for Infection Research (DZIF), Clinical Tuberculosis Unit, Borstel, Germany.; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany.; Department of Medicine, Karolinska Institute, Stockholm, Sweden., Cambau E; National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -Hôpital Lariboisière, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France., Wallace RJ Jr; Mycobacteria/Nocardia Laboratory, Department of Microbiology, The University of Texas Health Science Center, Tyler, Texas, USA., Andrejak C; Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France.; EA 4294, AGIR, Jules Verne Picardy University, Amiens, France., Böttger EC; Institute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland., Brozek J; Department of Clinical Epidemiology & Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada., Griffith DE; Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, Texas, USA., Guglielmetti L; National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -Hôpital Lariboisière, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France.; Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche 7, INSERM, IAME UMR1137, Paris, France., Huitt GA; Department of Medicine, National Jewish Health, Denver, Colorado, USA.; Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Knight SL; Library and Knowledge Services, National Jewish Health, Denver, Colorado, USA., Leitman P; NTM Info & Research, Miami, Florida, USA., Marras TK; Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario, Canada., Olivier KN; Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA., Santin M; Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Stout JE; Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA., Tortoli E; Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., van Ingen J; Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands., Wagner D; Division of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Winthrop KL; Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2020 Aug 14; Vol. 71 (4), pp. e1-e36.
DOI:	10.1093/cid/ciaa241
Abstrakt:	Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases. (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. This is a joint publication between Clinical Infectious Diseases and the European Respiratory Journal. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu